Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study - PubMed (original) (raw)
Clinical Trial
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study
Benjamin Weide et al. Cancer Immunol Immunother. 2017 Apr.
Abstract
Treatment of advanced melanoma patients with ipilimumab results in improved survival. However, only about 20% of treated patients experience long-term benefit. Combining treatment of ipilimumab with other drugs may improve immune activation and potentially enhance clinical efficacy. The aims of the phase II clinical trial reported here were to investigate tolerability and efficacy of a combined immunotherapeutic strategy comprising standard systemic ipilimumab at 3 mg/kg four times at 3-week intervals and intratumorally injected IL-2 at 9 MIU daily twice weekly for four weeks in pretreated melanoma patients with distant metastasis. The primary endpoint was the disease control rate according to immune-related response criteria at week 12; tolerability according to Common Terminology Criteria for Adverse Events criteria was secondary endpoint. No objective responses were observed in the 15 enrolled patients. Three patients had stable disease 12 weeks after starting treatment, yielding a disease control rate of 20%. Tolerability of this combination treatment was acceptable. Observed adverse events were those expected from the respective monotherapies. Autoimmune colitis was observed in two patients. Grade III/IV adverse events were observed in 40% of patients, and no treatment-related deaths occurred. Thus, this combined immunotherapy is associated with adverse events similar to those associated with the respective monotherapies. However, this study does not provide any evidence of improved efficacy of the combination over ipilimumab alone.
Keywords: Clinical trial; Interleukin-2; Ipilimumab; Melanoma.
Conflict of interest statement
B Weide reports receiving commercial research grants from Bristol–Myers Squibb (BMS) and MSD Sharp and Dohme (MSD) and reports receiving travel/accommodations/expenses from BMS, MSD, Roche, Amgen, Philogen, Curevac and compensated advisory services for MSD, BMS, Philogen and Curevac. C. Garbe reports receiving honoraria from BMS, MSD, Amgen, Novartis, Roche, GlaxoSmithKline (GSK) and reports receiving commercial research grants from MSD, BMS, Roche, GSK. T.K Eigentler reports receiving honoraria from BMS, MSD, Roche and Novartis, travel/accommodations/expenses from BMS and is a consultant/advisory board member for BMS. No potential conflicts of interest were disclosed by the other authors.
Figures
Fig. 1
Overall survival of the entire cohort. Kaplan–Meier analysis representing overall survival following combined immunotherapy comprising intratumoral IL-2 and systemic ipilimumab treatment for 15 included patients. Censored patients are indicated by vertical lines
Similar articles
- A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.
Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. Ray A, et al. Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453. Oncotarget. 2016. PMID: 27391442 Free PMC article. Clinical Trial. - Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Weber JS, et al. Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269740 Free PMC article. Clinical Trial. - A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. Weber J, et al. Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671877 Clinical Trial. - Systemic treatments for metastatic cutaneous melanoma.
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review. - Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ. Olszanski AJ. J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346. J Manag Care Spec Pharm. 2014. PMID: 24684639 Free PMC article. Review.
Cited by
- Does Use of Intratumoral Injections in Solid Tumor Malignancies Improve Outcomes and Reduce Adverse Events? An Integrative Review.
Matyola M, Martinez A, Dains J. Matyola M, et al. J Adv Pract Oncol. 2024 Jan;15(1):36-42. doi: 10.6004/jadpro.2024.15.1.4. Epub 2024 Jan 1. J Adv Pract Oncol. 2024. PMID: 39055366 Free PMC article. Review. - Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress.
DePalo DK, Zager JS. DePalo DK, et al. Cancers (Basel). 2023 Feb 23;15(5):1404. doi: 10.3390/cancers15051404. Cancers (Basel). 2023. PMID: 36900196 Free PMC article. Review. - Melanoma therapeutics: a literature review.
Dhanyamraju PK, Patel TN. Dhanyamraju PK, et al. J Biomed Res. 2022 Feb 28;36(2):77-97. doi: 10.7555/JBR.36.20210163. J Biomed Res. 2022. PMID: 35260531 Free PMC article. - Biosurfactants as Anticancer Agents: Glycolipids Affect Skin Cells in a Differential Manner Dependent on Chemical Structure.
Adu SA, Twigg MS, Naughton PJ, Marchant R, Banat IM. Adu SA, et al. Pharmaceutics. 2022 Feb 4;14(2):360. doi: 10.3390/pharmaceutics14020360. Pharmaceutics. 2022. PMID: 35214090 Free PMC article. - A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.
Kiyohara E, Tanemura A, Sakura K, Nakajima T, Myoui A, Yamazaki N, Kiyohara Y, Katayama I, Fujimoto M, Kaneda Y. Kiyohara E, et al. Cancer Immunol Immunother. 2022 Aug;71(8):2041-2049. doi: 10.1007/s00262-021-03122-z. Epub 2022 Jan 5. Cancer Immunol Immunother. 2022. PMID: 34984539 Free PMC article. Clinical Trial.
References
- Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol. 1994;5(2):179–181. doi: 10.1093/oxfordjournals.annonc.a058774. - DOI - PubMed
- Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21(15):2883–2888. doi: 10.1200/JCO.2003.07.116. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical